MRNA vaccine aims to prevent shingles in older adults
NCT ID NCT07400003
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new mRNA vaccine to prevent shingles (herpes zoster) in adults aged 40 and older. The vaccine uses mRNA technology, similar to some COVID-19 vaccines, and is freeze-dried for easier storage. Researchers will compare different doses against existing vaccines and a placebo to see which is safest and most effective at triggering immunity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lyophilized herpes zoster virus mRNA vaccine
What this could lead to
If successful, this could lead to a new, more effective shingles vaccine that is easier to store and transport.
What could go wrong
This is an early phase 1/2 trial, so safety and effectiveness are not yet proven. The vaccine may cause side effects or fail to generate a strong immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention
RECRUITINGXinjiang, 831100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••